Multiple Myeloma Clinical Trials

350 recruiting

Multiple Myeloma Trials at a Glance

475 actively recruiting trials for multiple myeloma are listed on ClinicalTrialsFinder across 6 cities in 53 countries. The largest study group is Phase 2 with 183 trials, with the heaviest enrollment activity in New York, Boston, and Atlanta. Lead sponsors running multiple myeloma studies include Institute of Hematology & Blood Diseases Hospital, China, Memorial Sloan Kettering Cancer Center, and Janssen Research & Development, LLC.

Browse multiple myeloma trials by phase

Treatments under study

About Multiple Myeloma Clinical Trials

Looking for clinical trials for Multiple Myeloma? There are currently 350 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Multiple Myeloma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Multiple Myeloma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 475 trials

Recruiting
Phase 2

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

Multiple Myeloma
National Cancer Institute (NCI)78 enrolled74 locationsNCT06179888
Recruiting
Phase 2

18F-Fluciclovine PET/CT in Multiple Myeloma

Multiple MyelomaNewly Diagnosed Multiple Myeloma (NDMM)Relapsed and/or Refractory Multiple Myeloma (RRMM)
National Cancer Institute (NCI)60 enrolled1 locationNCT06103838
Recruiting
Not Applicable

PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.

Multiple MyelomaComplication
Centre Leon Berard204 enrolled1 locationNCT05947136
Recruiting
Phase 3

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Relapsed or Refractory Multiple Myeloma
Celgene810 enrolled266 locationsNCT05519085
Recruiting

Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Living With a Myeloma in West-Occitanie"

Multiple Myeloma
University Hospital, Toulouse2,000 enrolled1 locationNCT04888039
Recruiting

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

Multiple MyelomaLymphoma, Non-HodgkinLeukemia-Lymphoma, Adult T-Cell+1 more
National Cancer Institute (NCI)500 enrolled1 locationNCT02682667
Recruiting

Tissue Collection for Studies of Lymph Cancer

Multiple MyelomaLymphoma, Non-HodgkinLeukemia-Lymphoma, Adult T-Cell+2 more
National Cancer Institute (NCI)1,295 enrolled2 locationsNCT01676805
Recruiting
Phase 1

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

Multiple Myeloma
AstraZeneca40 enrolled13 locationsNCT07073547
Recruiting
Phase 2

Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

Multiple Myeloma
Noffar Bar50 enrolled2 locationsNCT06993675
Recruiting
Not Applicable

FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease

Multiple MyelomaMonoclonal Gammopathy of Undetermined SignificanceSmoldering Multiple Myeloma
University of Miami120 enrolled1 locationNCT07446777
Recruiting
Phase 1

Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma

Multiple Myeloma
Washington University School of Medicine25 enrolled1 locationNCT06185751
Recruiting
Phase 2

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

Multiple Myeloma (MM)Multiple Myeloma, Newly Diagnosed
SCRI Development Innovations, LLC100 enrolled11 locationsNCT06974786
Recruiting
Phase 2

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

Multiple Myeloma
GlaxoSmithKline200 enrolled6 locationsNCT07227311
Recruiting
Phase 2

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

Multiple Myeloma
Memorial Sloan Kettering Cancer Center215 enrolled7 locationsNCT06679829
Recruiting
Not Applicable

"Pseudo-scanner" MRI Sequences for the Detection of Bone Lesions in Multiple Myeloma

Multiple Myeloma Bone Disease
Cliniques universitaires Saint-Luc- Université Catholique de Louvain45 enrolled1 locationNCT06988020
Recruiting
Phase 2

Outpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma

Refractory Multiple Myeloma
Ontario Clinical Oncology Group (OCOG)40 enrolled5 locationsNCT06421675
Recruiting
Phase 3

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Relapsed and/or Refractory Multiple Myeloma (RRMM)
Regeneron Pharmaceuticals915 enrolled14 locationsNCT07222761
Recruiting

Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution

Smoldering Multiple Myeloma (SMM)Monoclonal Gammopathy of Undetermined Significance (MGUS)Multiple Myeloma (MM)
Azienda USL Reggio Emilia - IRCCS60 enrolled4 locationsNCT07214324
Recruiting
Phase 1

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma in Relapse
Kelonia Therapeutics, Inc.70 enrolled7 locationsNCT07075185
Recruiting
Phase 3

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

Multiple Myeloma
Pfizer1,116 enrolled89 locationsNCT05623020